Publications

Journal Article Ppublish 147 citations
Electronic publication date
December 23, 2017

View on Pubmed.gov 27393509 | View on doi.org 10.1016/j.lungc...

Clinical and pathologic features of lung cancer expressing programmed cell death ligand 1 (PD-L1).

Search for publications in this journal Lung Cancer

Abstract

BACKGROUND

Programmed cell death 1 (PD-1) negatively regulates antigen receptor signaling upon binding by either of its ligands, programmed cell death ligand 1 or 2 (PD-L1/2). Blockade of this interaction with either PD-1 or PD-L1 antibodies has been successful in the treatment of human cancer, especially melanoma and non-small cell lung cancer. PD-L1 expression has been proposed as a predictor of tumor response. However, the relationships between PD-L1 expression and various clinicopathological characteristics remain unclear.

MATERIALS AND METHODS

PD-L1 expression was examined in 220 non-small cell lung cancer specimens that were consecutively resected at our hospital after validating the E1L3N antibody immunohistochemical assay by comparing IHC and RT-PCR data for lung cancer cell lines. We evaluated the relationships between PD-L1 positivity, several clinical factors and the immunohistochemical expression of epithelial-mesenchymal transition (EMT), cancer stem cell and proliferative markers.

RESULTS

PD-L1 was expressed in 22% of lung adenocarcinomas and 60% of squamous cell lung cancers. There was no significant association between PD-L1 expression and clinicopathological features in squamous cell lung cancer. However, in patients with lung adenocarcinoma, PD-L1 expression was significantly correlated with solid subtype histology, vimentin expression, increased Ki-67 labeling index and poor prognosis by multivariate analysis.

CONCLUSION

PD-L1 expression was associated with high proliferative activity and the EMT phenotype in adenocarcinoma but not in squamous cell carcinoma of the lung. PD-L1 expression was a significant poor prognostic factor in patients with lung adenocarcinoma.

References

No references provided.

Cited by 147 citations (total)

Journal Article Research Support, Non-U.S. Gov't

Alteration of PD-L1 expression and its prognostic impact after concurrent chemoradiation therapy in non-small cell lung cancer patients.

Electronic publication date June 22, 2019

Search for publications in this journal Sci Rep

Daichi Fujimoto [...] Keisuke Tomii et al.

Concurrent chemoradiation therapy (CCRT) is the treatment of choice for locally advanced non-small cell lung cancer (LA-NSCLC). Several clinical trials...

Journal Article

Relationship of Metabolic Alterations and PD-L1 Expression in Cisplatin Resistant Lung Cancer.

Electronic publication date August 19, 2017

Search for publications in this journal Cell Dev Biol

M Wangpaichitr [...] N Savaraj et al.

Despite numerous reports on immune checkpoint inhibitor for the treatment of non-small cell lung cancer (NSCLC), the response rate remains...

Conflict of interest statement

No conflict of interest statement provided.

MeSH

Specialties

Substances

Copyright

Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.